Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway [0.03%]
癌症治疗中的免疫检查点：程序性死亡受体-1(PD-1)通路为重点
Parisa Momtaz,Michael A Postow
Parisa Momtaz
T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and programmed cell death (PD)-1 receptor and its ...
Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder [0.03%]
儿童注意缺陷多动障碍的药物遗传学应用
Florence Levy
Florence Levy
This review examines molecular genetic studies shown to be of importance in the etiology of attention-deficit/hyperactivity disorder (ADHD) and contrasts prefrontal versus sub-cortical mechanisms. Although these mechanisms are not completel...
Julieta Trinks,María Laura Hulaniuk,María Ana Redal et al.
Julieta Trinks et al.
Hepatitis C virus (HCV) was identified for the first time more than 20 years ago. Since then, several studies have highlighted the complicated aspects of this viral infection in relation to its worldwide prevalence, its clinical presentatio...
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine [0.03%]
采用曲妥珠单抗-美坦辛偶联物对HER2阳性乳腺癌进行分层和靶向治疗
Saeed Sadeghi,Olga Olevsky,Sara A Hurvitz
Saeed Sadeghi
Purpose: This article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clinical data relating to its use for human growth factor receptor 2 (HER2)-positive breast cancer, potential pathways of re...
Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders [0.03%]
精神障碍患者迟发性运动障碍药物基因组学研究的临床意义
Florence Cf Chang,Victor Sc Fung
Florence Cf Chang
Pharmacogenomics is the study of the effects of genetic polymorphisms on medication pharmacokinetics and pharmacodynamics. It offers advantages in predicting drug efficacy and/or toxicity and has already changed clinical practice in many fi...
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition [0.03%]
三阴性乳腺癌的新型治疗策略：多聚（腺苷二磷酸核糖）聚合酶抑制的新作用
M William Audeh
M William Audeh
Inhibitors of the poly(adenosine triphosphate-ribose) polymerase (PARP)-1 enzyme induce synthetic lethality in cancers with ineffective DNA (DNA) repair or homologous repair deficiency, and have shown promising clinical activity in cancers ...
Susanne B Haga,Rachel Mills,Jivan Moaddeb
Susanne B Haga
Advances in pharmacogenetic research have improved our understanding of adverse drug responses and have led to the development of pharmacogenetic tests and targeted drugs. However, the extent of the communication process and provision of in...
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer [0.03%]
下一代EGFR抑制剂在非小细胞肺癌个体化治疗中的应用展望
Timothy A Yap,Sanjay Popat
Timothy A Yap
The use of genomics to discover novel targets and biomarkers has placed the field of oncology at the forefront of precision medicine. First-generation epidermal growth factor receptor (EGFR) inhibitors have transformed the therapeutic lands...
Developing genomic knowledge bases and databases to support clinical management: current perspectives [0.03%]
开发基因组知识库和数据库以支持临床管理：当前观点
Vojtech Huser,Murat Sincan,James J Cimino
Vojtech Huser
Personalized medicine, the ability to tailor diagnostic and treatment decisions for individual patients, is seen as the evolution of modern medicine. We characterize here the informatics resources available today or envisioned in the near f...
Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling [0.03%]
心力衰竭的个体化治疗：肾上腺素受体信号转导的药理基因组学研究
Grazia Daniela Femminella,Vincenzo Barrese,Nicola Ferrara et al.
Grazia Daniela Femminella et al.
Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part...